Targeted Cancer Therapeutics with Higher Efficacy and Safety
The company is currently developing several drug candidates:
- We have developed a lead Peptide Drug Conjugate (PDC) targeting a specific receptor highly expressed in solid tumors. Our lead PDC showed a dramatic tumor growth inhibition of multiple triple-negative breast cancer models. A single intravenous injection of 1.4 mg/kg of the new lead PDC caused a 100% tumor growth inhibition of HCC1806 TNBC model with the majority of mice showing complete response. Toxicology studies showed no effect on animal weight, white blood cells or normal organs, suggesting the safety of our new drug conjugate. We have also found that a suboptimal dose of our initial drug conjugate enhances the anti-tumor activity of anti-PD1 Keytruda using humanized mice bearing BR1126 TNBC patient-derived tumor model. We are looking forward to perform additional oncology and immuno-oncology studies of our lead drug conjugate alone or in combination therapy on preclinical models of metastatic TNBC, ovarian and endometrial patient-derived tumors as well as PK/biodistribution/toxicology studies in cynomolgus monkey. Our goal is to file an IND application to the FDA and initiate Phase 1/2a clinical trial of the lead drug conjugate as monotherapy or combination therapy on patients with metastatic TNBC, ovarian and endometrial cancers.
- We are also developing another PDC targeting a different receptor highly expressed in many solid tumors to be used as monotherapy or combination therapy.
- We also plan to test well designed bispecific drug conjugates for the treatment of advanced and metastatic solid tumors.